We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Affimed NV | NASDAQ:AFMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.38 | -6.92% | 5.11 | 5.10 | 5.28 | 5.49 | 5.10 | 5.49 | 38,916 | 17:39:58 |
Per ASCO, the decision was solely based on its embargo policy which restricts data in submitted abstracts from presentation at any prior conference or forum. Data from AFM13-104 was recently presented in an oral session at the Annual Meeting of the American Association for Cancer Research (AACR) on April 10, 2022, in New Orleans, Louisiana.
The removal of the presentation is not related to the status or results of the ongoing trial. Affimed respects ASCO’s decision and is working with The University of Texas MD Anderson Cancer Center on plans to submit additional data on AFM13-104 to a future scientific forum.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander FudukidisDirector, Investor RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: m.sandin@affimed.com Tel.: +1 (484) 888-8195
1 Year Affimed NV Chart |
1 Month Affimed NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions